EGFR and non-small cell lung carcinoma: Patients with non-small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase are at high risk of developing metastasis following the emergence of therapy-resistance to EGFR targeted therapies [4, 5].